Influence of Growth Hormone and Additives on In vitro Shoot Initiation from Apical and Axillary Meristems of Commiphora wightii

Commiphora wightii is an important plant species of immense medicinal value and pharmaceutically used for the treatment of various diseases. The present study was designed to develop an efficient protocol for micropropagation of Commiphora wightii from apical and nodal meristems and to study the influence of additives on the enhancement of bud breaking, number of shoot per explant and shoot length. MS (Murashige and Skoog, 1962) basal media supplemented with various concentrations of 6- Benzyl amino purine (BAP: 0.5-5.0 mg/l) alone or in combinations with kinetin (KN: 0.5-1.0 mg/l) and naphthalene acetic acid (NAA: 0.5-1.0 mg/l) and additives like ascorbic acid (AA), citric acid (CA), adenine sulphate (AS) and activated charcoal (AC). The highest shoot initiation was reported in T13 (MS + 4.0BAP + 1.0 NAA mg/l + Additives) i.e. 0.80 ± 0.07 with highest number (1.57 ± 0.15) of shoots per explants. Treatment T12 (MS + 3.0BAP + 1.0 NAA+1.0 KN mg/l + Additives) highest shoot length (1.13) was recorded followed by T13 (MS + 4.0BAP + 1.0 NAA mg/l Additives) and T14 (MS + 5.0BAP + 1.0 KN) having mean value 1.07 and 0.90 respectively. MS basal medium (control) devoid of growth regulators did not support the shoot induction. The shoot induction protocol developed in current study provides a basis for germplasm conservation and for further investigation of medicinally active constituents of the elite medicinal plant Keywords:  Commiphora wightii, 6- Benzyl amino purine, kinetin, naphthalene acetic acid, additives

Commiphora wightii (Arn.) Bhandari. Review of Its Botany, Medicinal Uses, Pharmacological Activities and Phytochemistry

The oldest remedies identified to mankind are herbal medicines. India is recognized worldwide for its Ayurvedic treatment. As only little studies are done on this plant, the purpose of current review is to make accessible up-to-date information on, botany, morphology, ecological biodiversity, medicinal uses, phytochemistry and pharmacological activities on diverse parts of Commiphora wightii (Arn.) Bhandari (C. wightii). This review was assembled using scientific literature from electronic search engine such as Springerlink, BioMed Central, PubMed, Scopus, ScienceDirect, Scielo, Medline and Science domain. Supplementary literatures were obtained from books, book chapters, dissertations, websites and other scientific publications. C. wightii  (Syn. Commiphora mukul Hook. ex. Stocks) or Guggulu tree. C. wightii is a shrub or small tree belonging to Burseraceae family. C. wightii contains volatile oil, gum resin, gugulipids, guggulsterones, guggulsterols, mukolol and other steroids. Guggulu is very much used in Ayuvedic system of medicine as astringent, anti-septic, expectorant, aphrodisiac, carminative, anti-spasmodic, emmenagogue. In Ayurveda, it is the best among herbs that are used for Medoroga and Vata disorders. It is widely used for obesity and it is also known as fat burning agent all over the world. It helps to lower cholesterol and triglycerides level. It is very effective in rheumatoid arthritis, gout and sciatica. It is also one of the most important Rasayana of Ayurveda. In addition it treats sluggish liver, stimulates libido, nervous diseases, bronchial congestion, cardiac and circulatory problems, weak digestion, wounds, abscess, foetid ear, fractures, gynaecological problems and various skin diseases. C. wightii is a very important and trustworthy herb in Ayurvedic medicine. This alternative system of medicine is gaining increasing fame universal. There is a required to isolate active constituents, their biological test, molecular mechanisms, experimental defense and legalization of therapeutic uses of C. wightii. The collected information will be obliging to locate up study protocol for current drugs and Ayurvedic formulation extension in remedial and luxury a variety of ailments.  &nbsp

A rare case of cervical fibroid presenting as retained placenta with postpartum hemorrhage

Fibroids during pregnancy are often asymptomatic but sometimes may lead to various complications and unusual presentations. We are reporting an unusual case of cervical fibroid during pregnancy that presented as retained placenta with postpartum hemorrhage following a full term normal vaginal delivery

Leukemic pleural effusion in AML-M0: Unusual presentation

Extramedullary disease in AML-M0 is a rare occurrence. It is even rarer to encounter breathlessness as primary presenting complaint secondary to a leukemic pleural effusion. Leukemic pleural effusion occurs rarely in acute myeloid leukemia (AML) with minimal differentiation. Patients with AML usually present with weakness, hemorrhage, and recurrent infections. The highest incidence of extramedullary leukemic manifestation is seen in monocytic AML. Here, we report the case of an 18-year-old male who presented withbreathlessness and vocal cord palsy. Examination and investigation established diagnosis of an acute myeloid leukemia M0 with leukemic pleural effusion

Theoretical prediction and experimental study of a ferromagnetic shape memory alloy: Ga_2MnNi

We predict the existence of a new ferromagnetic shape memory alloy Ga_2MnNi using density functional theory. The martensitic start temperature (T_M) is found to be approximately proportional to the stabilization energy of the martensitic phase (deltaE_tot) for different shape memory alloys. Experimental studies performed to verify the theoretical results show that Ga_2MnNi is ferromagnetic at room temperature and the T_M and T_C are 780K and 330K, respectively. Both from theory and experiment, the martensitic transition is found to be volume conserving that is indicative of shape memory behavior.Comment: 11 pages, 3 figure

Cu based Metal Organic Framework (Cu-MOF) for electrocatalytic hydrogen evolution reaction

Hydrogen production using novel catalysts is regarded as one of the most needed technology for the future economic needs and water splitting to give H2 gas, which is a challenging task for large-scale production. This work reports the synthesis of Meso-Cu-BTC metal organic framework and further used for understanding its role in electrochemical hydrogen evolution reaction (HER) in 1 M NaOH solution. Meso-Cu-BTC electrocatalyst showed a less overpotential of 89.32 mV and an onset potential of 25 mV with an appreciable current density. Results show a low Tafel slope of 33.41 mVdec−1 and long-term durability. Thus, the overall results show that Meso-Cu-BTC acted as a good candidate for electrocatalysis towards hydrogen evolution

Spin-Valve-Like Magnetoresistance in Mn2NiGa at Room Temperature

Spin valves have revolutionized the field of magnetic recording and memory devices. Spin valves are generally realized in thin film heterostructures, where two ferromagnetic (FM) layers are separated by a nonmagnetic conducting layer. Here, we demonstrate spin-valve-like magnetoresistance at room temperature in a bulk ferrimagnetic material that exhibits a magnetic shape memory effect. The origin of this unexpected behavior in Mn2NiGa has been investigated by neutron diffraction, magnetization, and ab initiotheoretical calculations. The refinement of the neutron diffraction pattern shows the presence of antisite disorder where about 13% of the Ga sites are occupied by Mn atoms. On the basis of the magnetic structure obtained from neutron diffraction and theoretical calculations, we establish that these antisite defects cause the formation of FM nanoclusters with parallel alignment of Mn spin moments in a Mn2NiGa bulk lattice that has antiparallel Mn spin moments. The direction of the Mn moments in the soft FM cluster reverses with the external magnetic field. This causes a rotation or tilt in the antiparallel Mn moments at the cluster-lattice interface resulting in the observed asymmetry in magnetoresistance

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019

Background: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH

Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019

Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease and pulmonary sarcoidosis, and other CRDs, from 1990 to 2019 by sex, age, region, and Socio-demographic Index (SDI) in 204 countries and territories. Deaths and DALYs from CRDs attributable to each risk factor were estimated according to relative risks, risk exposure, and the theoretical minimum risk exposure level input. Findings: In 2019, CRDs were the third leading cause of death responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) with a prevalence of 454.6 million cases (417.4–499.1) globally. While the total deaths and prevalence of CRDs have increased by 28.5% and 39.8%, the age-standardised rates have dropped by 41.7% and 16.9% from 1990 to 2019, respectively. COPD, with 212.3 million (200.4–225.1) prevalent cases, was the primary cause of deaths from CRDs, accounting for 3.3 million (2.9–3.6) deaths. With 262.4 million (224.1–309.5) prevalent cases, asthma had the highest prevalence among CRDs. The age-standardised rates of all burden measures of COPD, asthma, and pneumoconiosis have reduced globally from 1990 to 2019. Nevertheless, the age-standardised rates of incidence and prevalence of interstitial lung disease and pulmonary sarcoidosis have increased throughout this period. Low- and low-middle SDI countries had the highest age-standardised death and DALYs rates while the high SDI quintile had the highest prevalence rate of CRDs. The highest deaths and DALYs from CRDs were attributed to smoking globally, followed by air pollution and occupational risks. Non-optimal temperature and high body-mass index were additional risk factors for COPD and asthma, respectively. Interpretation: Albeit the age-standardised prevalence, death, and DALYs rates of CRDs have decreased, they still cause a substantial burden and deaths worldwide. The high death and DALYs rates in low and low-middle SDI countries highlights the urgent need for improved preventive, diagnostic, and therapeutic measures. Global strategies for tobacco control, enhancing air quality, reducing occupational hazards, and fostering clean cooking fuels are crucial steps in reducing the burden of CRDs, especially in low- and lower-middle income countries

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe